Anticoagulant factor concentrates in disseminated intravascular coagulation: Rationale for use and clinical experience

Seminars in Thrombosis and Hemostasis

Volumn 27, Issue 6, 2001, Pages 667-674

  De Jonge, E ^a   Van der Poll, T ^a   Kesecioglu, J ^a   Levi, M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Antithrombin; Inflammation; Protein C; Sepsis; TFPI; Tissue factor pathway inhibitor

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; BLOOD CLOTTING INHIBITOR; PROTEIN C; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; DISSEMINATED INTRAVASCULAR CLOTTING; EXPERIMENTAL INFECTION; HUMAN; INFLAMMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SEPSIS;

ANTITHROMBINS; BLOOD COAGULATION; CLINICAL TRIALS; DISSEMINATED INTRAVASCULAR COAGULATION; HUMANS; LIPOPROTEINS; PROTEIN C; SEPSIS;

EID: 0035216020     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-18871     Document Type: Article

References (104)

1. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies
2. Current drug treatment strategies for disseminated intravascular coagulation
3. Disseminated intravascular coagulation
4. Tumor necrosis factor-induced endothelial tissue factor is associated with subendothelial matrix vesicles but is not expressed on the apical surface
5. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease
6. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque
7. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: Related to an unfavourable prognosis
8. The endotoxin-induced coagulant activity of human monocytes
9. Induction of endothelial tissue factor by endotoxin and its precursors
10. Hemostasis and malignancy
11. Monocytes and tissue factor promote thrombosis in a murine model of oxygen deprivation
12. Mechanism of tissue factor activation on HL-60 cells
13. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees
14. Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-Cl(-)-inhibitor complexes in sepsis
15. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody
16. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli
17. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock
18. Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity
19. Antithrombin: Its physiological importance and role in DIC
20. New potential therapeutic modalities: Antithrombin III
21. Clinical relevance of antithrombin deficiencies
22. Acquired antithrombin III deficiency: Laboratory diagnosis, incidence, clinical implications, and treatment with antithrombin III concentrate
23. The disturbance of hemostasis in septic shock: Role of neutrophil elastase and thrombin, effects of antithrombin III and plasma substitution
24. Antithrombin 3. Protection against death after injection of thromboplastin
25. Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons
26. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli
27. The suprapharmacologic dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: Substantial reduction in mortality and morbidity
28. Antithrombin III in animal models of sepsis and organ failure
29. Combined antithrombin III and C1-esterase inhibitor treatment decreases intravascular fibrin deposition and attenuates cardiorespiratory impairment in rabbits exposed to Escherichia coli endotoxin
30. Substitution of antithrombin III in shock and DIC: A randomized study
31. Therapeutic use of antithrombin III in shock and disseminated intravascular coagulation
32. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation
33. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: A controlled double-blind, randomized, multicenter study
34. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis
35. Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis
36. Antithrombin III supplementation in severe sepsis: Beneficial effects on organ dysfunction
37. Disseminated intravascular coagulation
38. Clinical evaluation of antithrombin III concentrate (BI 6.013) for disseminated intravascular coagulation in obstetrics. Well-controlled multicenter trial
39. Antithrombin III in patients with severe sepsis: A pharmacokinetic study
40. Antithrombin in severe sepsis - "New" indication of an "old" drug?
41. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate
42. Endothelial protein C receptor
43. Coagulation activation and tissue necrosis in meningococcal septic shock: Severely reduced protein C levels predict a high mortality
44. Protein S, C4b binding protein, and the hypercoagulable state
45. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity
46. Modulation of endothelial cell hemostatic properties by tumor necrosis factor
47. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor
48. Release of thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils: In vivo and in vitro studies
49. Eosinophil cationic granule proteins impair thrombomodulin function. A potential mechanism for thromboembolism in hypereosinophilic heart disease
50. Protein C, protein S and C4b-binding protein in severe infection and septic shock
51. Human urinary soluble thrombomodulin (MR-33) improves disseminated intravascular coagulation without affecting bleeding time in rats: Comparison with low molecular weight heparin
52. Effect of human urinary thrombomodulin on endotoxin-induced intravascular coagulation and pulmonary vascular injury in rats
53. The antithrombotic effects of recombinant human soluble thrombomodulin (rhsTM) on tissue factor-induced disseminated intravascular coagulation in crab-eating monkeys (Macaca fascicularis)
54. rhs-TM prevents ET-induced increase in pulmonary vascular permeability through protein C activation
55. A novel recombinant soluble human thrombomodulin, ART-123, activates the protein C pathway in healthy male volunteers
56. Pharmacokinetics and safety of a novel recombinant soluble human thrombomodulin, ART-123, in healthy male volunteers
57. Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation
58. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon
59. Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans
60. Protein C substitution in sepsis-associated purpura fulminans
61. Treatment of purpura fulminans in meningococcemia with protein C concentrate
62. Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans
63. Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: Treatment with protein C concentrate
64. Recombinant human activated protein C (rhAPC) produces a trend toward improvement in morbidity and 28 day survival in patients with severe sepsis
65. Efficacy and safety of recombinanat human activated protein C for severe sepsis
66. C4b-binding protein exacerbates the host response to Escherichia coli
67. New potential therapeutic modalities: Tissue factor pathway inhibitor
68. Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock
69. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia
70. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor
71. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma
72. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor
73. Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators
74. Tissue factor pathway inhibitor: From unknown coagulation inhibitor to major antithrombotic principle
75. Plasma tissue factor pathway inhibitor in disseminated intravascular coagulation: Comparison of its behavior with plasma tissue factor
76. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples
77. Tissue factor pathway inhibitor and Von Willebrand factor antigen levels in adult respiratory distress syndrome and in a primate model of sepsis
78. Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in the rabbit
79. The effect of two-domain tissue factor pathway inhibitor on endotoxin-induced disseminated intravascular coagulation in rabbits
80. Attenuation of tissue thrombosis and hemorrhage by ala-TFPI does not account for its protection against E. coli - A comparative study of treated and untreated non-surviving baboons challenged with LD100 E. coli
81. Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with gram-negative peritonitis
82. The influence of reduced liver blood flow on the pharmacokinetics and pharmacodynamics of recombinant tissue factor pathway inhibitor
83. Introduction: Are natural anticoagulants candidates for modulating the inflammatory response to endotoxin?
84. Prolonged shock in the baboon subjected to infusion of E. coli endotoxin
85. DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage
86. Factor Xa as an interface between coagulation and inflammation. Molecular mimicry of factor Xa association with effector cell protease receptor-1 induces acute inflammation in vivo
87. Factor Xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells
88. Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation
89. Thrombin and factor Xa enhance the production of interleukin-1
90. Thrombin enhances monocyte secretion of tumor necrosis factor and interleukin-1 beta by two distinct mechanisms
91. Thrombin potently stimulates cytokine production in human vascular smooth muscle cells but not in mononuclear phagocytes
92. Thrombin stimulates production of interleukin-8 in human umbilical vein endothelial cells
93. A novel biologic activity of thrombin: Stimulation of monocyte chemotactic protein production
94. Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin
95. Thrombin activates nuclear factor-kappaB and potentiates endothelial cell activation by TNF
96. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin
97. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa
98. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester
99. Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte-dependent proliferative responses
100. Human protein C inhibits selectin-mediated cell adhesion: Role of unique fucosylated oligosaccharide
101. A model for thrombin protection against endotoxin
102. Activation of protein C in vivo
103. Tissue factor and factor VIIa receptor/ligand interactions induce proinflammatory effects in macrophages
104. Role of tissue factor in adhesion of mononuclear phagocytes to and trafficking through endothelium in vitro